Latest news
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
- Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes Press Release, Financial Results 26 February 2026 Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches authorised generic of Nucynta® (tapentadol) in the US Press Release, Product 25 February 2026 Hikma launches authorised generic of Nucynta® (tapentadol) in the US
- Notice of results Press Release, Financial Results 03 February 2026 Notice of results
- Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 19 January 2026 Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively
Related content